The coronavirus pandemic has shown all of us how major clinical issues can focus efforts across both business and academia, and how quickly researchers and companies can pivot to find solutions for critical and high value opportunities. While the COVID-19 pandemic is clearly an outlier in this regard, and it is clear that only a small percentage of all the technologies being developed will be successful, the technologies that can make it to market quickly and that are able to meet customer needs in the most efficient and economic manner will likely move forward.
Image: https://www.insideindianabusiness.com
